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There are conflicting reports on the differential effect of surgery performed during the two phases of the
menstrual cycle, namely, follicular and luteal, and prognosis of operable breast cancer. A statistical meta-analysis of
the published evidence suggests a modest survival benefit of 15 ± 4% when the operation is performed during the
lueteal phase. Further research in this area might provide a novel avenue to understand the natural history of breast
cancer. A spin off from these studies might be the understanding of the importance of events that occur at the time
of surgery in determining long term prognosis.
1. Introduction
The menstrual cycle is a rhythmic preparation for extrusion
of ovum and subsequent pregnancy if the ovum is fertilized.
The events are under the influence of the hypothalamic
gonadotrophins follicle stimulating hormone (FSH) and lu-
eteinizing hormone (LH) that regulate the release of sex
steroid hormones estrogen and progesterone from the
ovarian interstitium which in turn prime the ovarian follicles
and induce ovulation (figure 1). Assuming that day 0 is the
first day of menstrual flow of the last menstrual period, all
hormones are low for the first 4–5 days. This is the early
period of follicular development. Estrogens (ER) gradually
rises for the next 3–4 days
followed by a rapid peak by 12th day which is a day
before the LH and FSH peak. Ovulation occurs 24–36 h after
the LH peak by about the 14th day. The second peak of
estrogen occurs about a week after ovulation and is op-
posed by a progesterone peak. In addition progesterone
shows a small increase in concentration corresponding to
the LH surge. Hence estrogens remains unopposed during
the follicular phase, up to day 12 to be precise, and during
the rest of the cycle progesterone opposes the effects of
estrogen (Yen 1986).
2.  The first reports
The timing of surgery during the menstrual cycle and breast
cancer survival has been debated since the first report in
the Lancet in 1989 by Hrushesky et al (1989). They reported
on timing of surgery during the menstrual cycle in 41
women with operable breast cancer. Ten year survival was
95% for the 22 women who had their
tumours excised during peri-ovulatory period (days 7–20)
whereas it was 79% for the 19 women who had their
tumours resected during peri-menstrual period (7 days on
either side of the first day of the last menstrual period, days
0–6 and 21–36). Their selection of intervals was based on
murine experiments reported earlier by the group. Ratajczak
et al (1988) found that timing of resection of transplantable
breast tumours within the murine estrous cycle determined
the incidence of lung metastases and death of mice. Resec-
tion of tumour during proestrous phase had two and half
times better survival compared to resection during
metestrous phase. The proestrous phase is characterized by
a surge in lueteinizing and follicle stimulating hormone with
a background combination of progesterone and estrogen.
This approximately corresponds to the peri-ovulatory pe-
riod (7 days on either side of putative time of ovulation,
days 7–20) in human
menstrual cycle.
  The hypothesis was subsequently redefined by Badwe et
al (1991a) who suggested that resection of tumour during
the phase of unopposed estrogen may be deleterious for
survival. Badwe et al (1991a) compared survival of 75
women on whom surgery was performed during days
3–12 (unopposed estrogen phase) with 174 women who had
sec io  during the remainder of the menstrual cycle (days
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0–2, 13–32, N= 174). The overall survival at 10 years was
54% for unopposed estrogen group compared to 84% for
the other group (P < 0·001). On multivariate analysis, the
number of metastatic lymph nodes, timing of surgery, his-
tological type and age were significant determinants of sur-
vival.
3.  The hypothesis
‘The timing of surgery during the menstrual cycle and sur-
vival in breast cancer’ carries two distinct postulates. First,
hormonal milieu in the host can modulate metastatic poten-
tial of breast cancer and second, events at the time of sur-
gery can influence survival. It may be worthwhile examining
the evidence for and against these postulates and then de-
cide as to whether a prospective randomized study would
be justified.
4.  Hormones and breast cancer survival:
Clinical evidence
A deleterious effect of unopposed estrogen on survival was
deduced from poor survival in peri-menopausal women with
breast cancer (Langlands et al 1979; Caleffi and Fentiman
1989; Badwe and Hawaldar 1994). Natural cessation of
ovarian function is associated with repeated anovulatory
cycles before a true post-menopausal state is reached.
During these anovulatory cycles estrogen would be unop-
posed much more frequently, compared to pre-menopausal
women. The unopposed estrogen in these women would
still be much higher compared to that in post-menopausal
women.
  If unopposed estrogen is responsible for the deleterious
impact on survival, then the effect should be evident when-
ever women experience this state. In pre-menopausal
women during the follicular phase or days 3–12 of the men-
strual cycle, estrogen is unopposed. A meta-analysis (using
a fixed effect model) of all the published studies (Hrushesky
et al 1989; Badwe et al 1991a, b; Goldhirsch et al 1991, 1997;
Kurebayashi et al 1991; Low et al 1991; Powles t al 1991;
Rageth et al 1991; Sainsbury et al 1991; Senie et al 1991;
Stewart 1991; Ville et al 1991; Gnant et al 1992; Sigurdsson
1992; Callies 1993; Nathan et al 1993; Spratt et al 1993;
Stonelake et al 1993;
Wobbes et al 1993; Corder t al 1994; Engele et al 1994;
Jager and Sauerbrei 1994; Kroman et al 1994; Saad et al
1994; Sauerbrei et al 1994; Veronesi et al 1994; D’eredita et
al 1995; Holli et al 1995; von-Minckwitz
et al 1995; Levine et al 1996; Martinez-Lacaci and Dickson
1996; Tsuchiya et al 1996; Chag et al 1997; Mondini Guido
et al 1997; Vanek et al 1997; Zhang 1998) dealing with tim-
ing of surgery that allowed comparison of unpposed es-
trogenic phase versus opposed estrogenic phase, showed
an odds reduction (OR) of 15% with confidence intervals
± 4 (P = 0·003) (figure 2). The test for trend according to
year of publication is not significant and test for heteroge-
neity is significant (P < 0·001). Three (Ville et al 1991; Web-
bes et al 1993; Badwe et al 1994) of these studies have had
circulating serum progesterone and estrogen measured a
day or two on either side of the day of surgery. All three
studies showed a protective
effect of circulating progesterone on the event of metastasis
d death. The overall effect was OR 52·8 ± 32%, 2P < 0·001
( est of heterogeneity and trend NS, P > 0·2) (figure 3).
  Peri-menopausal and post-menopausal women are more
likely to have unopposed estrogen compared to pre-
menopausal women. In pre-menopausal women at least 50%
of the times estrogen will be opposed by progesterone. A
meta-analysis of 22 published studies examined the effect of
menop usal status or age at diagnosis on
either side of 50 years (Badwe and Hawaldar 1991).
Fifteen of the 22 studies revealed better survival in pre-
menopausal (or < 50 years of age) and 7 showed equivocal
result . The overall collated evidence showed a
significantly higher survival in pre-menopausal women (OR
0·76, CI 0·74–0·78, 2P < 0·0000001) with an odds reduction of
24 ± 1% (figure 4).
  In post-menopausal women, the source of estrogen is the
enzyme aromatase in body fat which converts precursors of
estrogen into active hormone (Grodin et al 1973). Obese
women produce more estrogen than thin women (Tricho-
poulos et al 1987) hence if unopposed estrogen is deleteri-
ous for survival, thin women should experience a better
survival than obese women with breast cancer. A meta-
analysis of eighteen studies (Badwe and Hawaldar 1991)
addressing obesity and breast cancer
survival supported a quantitative inverse relationship
between them. In 12 studies non-obese women had better
survival compared to obese women whereas 6 studies
showed equivocal results. None of the studies had obese
women with better survival in comparison to thin women.
The OR for thin women was 36·6 ± 3·7, 2P < 0·000001 (figure
5).Figure 1.  Variations in steroid sex hormones during the
menstrual cycle.
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5.  Hormones and breast cancer survival:
Laboratory evidence
Metastasis is a cascade of sequential steps involving multi-
ple tumour host interactions. Successful metastasis
involves migration of tumour cells from its primary organ to
a distant site in adequate numbers to establish a colony.
The first process of migration requires digestion of
surrounding tissue by tumour cells to gain access to lym-
phatic and blood vessels. Proteases bestow this invasive
ability upon tumour cells. There are at least two proteases
that are known to be modulated by estrogen in vitro.
Cathepsins (Rachfort et al 1988) and uPA (Saksela and
Rifkin 1988) are up-regulated in breast cancer cells by estro-
gen and the ability of the primary tumour to secrete these
two proteases has had inverse correlation to survival in
breast cancer (Rachfort et al 1988; Janicke et al 1989). Saad
et al (1998) recently reported increased expression of ca-
thepsin L, matrix metalloproteinase (MMP-9 and MMP-2)
and down regulation of tissue inhibitors of
metalloproteinases TIMP-1 and TIMP-2 in tumours
excised during the follicular phase of the menstrual cycle.
The invasive ability of the primary tumour was pathologi-
cally evaluated by the presence of vascular and lymphatic
invasion (LVI). The incidence of LVI has been found to
strongly correlate with unopposed estrogenic phase in pre-
menopausal women (Badwe et al 1995) and has a direct rela-
tion with obesity as assessed by body weight (Badwe e  al
1997). Tumour cells under the influence of estrogen could
secrete proteases thus increasing their invasive ability. The
products of digestion by protease would usurp ionic cal-
cium due to pH changes which in turn would
reduce the binding capacity of E cadherin (calcium depen-
dent) (Takeichi 1988). This would allow cells to migrate to
gain access to lymphatic and vascular channels to be car-
ried to distant sites. There are many other prognostic fac-
tors of operable breast cancer that have been shown to be
modulated unfavourably by estrogen. These include EGF
(Marques and Franco 1993) and Cyclin D (Altucci
et al 1996) that can induce proliferation of tumour cells and
allow them to nestle at distant sites. It is not only that tu-
mours manifest increased ability to invade and proliferate
but the host environment is also permissive under the
Figure 2.  Meta-analysis of studies on timing of surgery
during the menstrual cycle and survival in breast cancer. A
square and horizontal line demarcate each study. The
square represents the size and the event rate in the study.
The horizontal line indicates 95% confidence limits. A study
depicted to the left of unity (< 1) suggests superior outcome
in women who had surgery during the luteal phase whereas
that to the right of unity (> 1) indicates superior outcome in
women who had surgery during the follicular phase. The
diamond at the bottom indicates the overall effect which is
odds reduction of 15 ± 8% in favour of women who had
surgery during the luteal phase of the menstrual cycle.
Figure 3.  Meta-analysis of studies that measured serum
progesterone levels at the time of surgery and survival in
breast cancer. A square and horizontal line demarcate each
study. The square represents the size and the event rate in
the study. The horizontal line indicates 95% confidence
limits. A study depicted to the left of unity (< 1) suggests
superior outcome in women who had surgery when proges-
terone levels were > 5 ng/ml whereas that to the right of
unity (> 1) indicates superior outcome in women who had
surgery when progesterone levels were < 5 ng/ml. The dia-
mond at the bottom indicates
the overall effect which is odds reduction of 52·8%in favour
of women who had surgery during the luteal phase of the
menstrual cycle.
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Figure 4.  Meta-analysis of menopausal status and survival in breast cancer. A
square and horizontal line demarcate each study. The square represents the size and
the event rate in the study. The horizontal line indicates 95% confidence limits. A
study depicted to the left of unity (< 1) suggests superior outcome in pre-
menopausal women whereas that to the right of unity (> 1) i dicates superior out-
come in post-menopausal women. The diamond at the bottom indicates the overall
effect which is odds reduction of 24·7 ± 1% in favour of pre-menopausal women with
breast cancer.
Figure 5.  Meta-analysis of obesity and survival in breast cancer. A square and
horizontal line demarcate each study. The square represents the size and the event
rate in the study. The horizontal line indicates 95% confidence limits. A study de-
picted to the left of unity (< 1) suggests superior outcome in non-obese women
whereas that to the right of unity (> 1) indicates superior outcome in obese women.
The diamond at the bottom indicates the overall effect which is odds reduction of
36·6 ± 3·7% in favour of non-obese women with breast cancer.
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unopposed estrogenic influence. The NK cell activity is at
its lowest ebb during the follicular phase (Hanna and
Schnieder 1982).
6.  Events at the time of surgery and survival:
Clinical evidence
That the hormonal milieu during the menstrual cycle might
influence prognosis leads to the assumption that events at
the time of surgery are implicated in the long term survival
of breast cancer. Data from randomized
trials (Badwe and Vaidya 1996), modelling studies
(Baum and Badwe 1994), and the laboratory suggest that
the event of surgery influences the onset or autonomy of
distant micrometastases. In sharp contrast to rigorous test-
ing that have been undertaken for radiation and chemother-
apy in randomized trials [Early Breast Trialist’ Collaborative
Group (EBCTCG) 1990], the effect of surgery on survival
has never been tested. The best experiment to test surgical
dissemination/autonomy (SDA) hypothesis would be to
compare surgery versus no surgery; but such a trial would
be unethical.
  Randomized trials of screening offer the next best
opportunity to test the SDA hypothesis. In these trials the
event of surgery is delayed in the control group by about
18–24 months (lead-time) as compared to screened group;
hence the first few years of follow up should offer a com-
parison between surgery versus natural progression
in vivo. As the majority of cases undergo surgery eventu-
ally in either arm, a comparison between early surgery ver-
sus late surgery can be made. The conventional theory
(Fisher 1977) holds that surgery as an event does not
influence the natural history of cancer, and survival is de-
termined by the presence of micrometastases prior to diag-
nosis. The conventional theory would predict identical
number of deaths in both the groups for the first few years.
On the other hand, if dissemination/autonomy were to occur
at the time of surgery it would lead to excess deaths in
screened group for the first few years. A meta-analysis (El-
wood et al 1993) of annual cumulative mortality of all the
published screening trials in breast cancer revealed that
there was indeed an excess mortality in the screened group
in the first few years. In women above the age of 50 years
the excess mortality in the screened group was seen only in
the first year whereas in younger women it persisted for the
first 7 years after randomization
(table 1). An excess mortality in the screened group was
evident in both the randomized trials of screening for lung
cancer (Fontana 1985 and Kubik et al 1990) beyond 6 years
of follow up. In colon cancer screening trial
(Mandel et al 1993), the group that had biennial screening
for occult blood in stool, experienced excess deaths as
compared to control group for the first 10 years. Thus all the
published screening data suggest that early intervention in
the form of surgery had a detrimental effect on the natural
history of cancer in the first few years. A careful analysis of
the breast cancer screening data reveals that the ultimate
reduction in deaths due to breast cancer is the net effect of
early excess mortality in the screened group (a comparison
of surg ry vs no surgery) and later saving of lives (a com-
paris n of early surgery vs late surgery).
7.  Events at the time of surgery and survival:
Laboratory evidence
Laboratory evidence for surgical dissemination has been
available since the beginning of this century. Tyzzer (1913)
showed it in animal studies, Fisher and Turnbull (1955) in
portal vein blood samples in colon cancer and recently with
greater precision of PCR technology dissemination has
been demonstrated in prostate (Eschwege
et al 1995) and breast cancer (Brown et al 1994). Fisher t al
(1989) from animal experiments suggest outgrowth of metas-
tasis after the event of surgery and postulate that it may be
related to perturbation of balance between
inhibitory and stimulatory factors elaborated by the primary
tumour. Holmgren et al (1995) showed that the
removal of a primary Lewis lung carcinoma tumour in mice
resulted in the exponential growth of its lung metastases.
The presence of primary tumour elaborating angiostatin
which had anti-angiogenic property suppressed
outgrowth of micro-metastases.
8.  Conclusion
Deleterious effect of unopposed estrogen at the time of
surgery suggests that events at the time of surgery can
influence the long-term survival in breast cancer. It leads
one to explore the effect of surgery on the natural history of
breast cancer. It will be impossible to test this postulate as a
trial of surgery vs no surgery will be unethical. The best
opportunity to compare surgery vs no surgery is early years
Table 1.  Meta-analysis of data from screening trials for
breast cancer (Elwood et al 1993).
Ratio of average cumulative mortality:
Screened/control
Years after
randomization Age < 50 yr Age > 50 yr
  1 1·67 1·62
  2 1·05 0·69
  3 1·88 0·76
  4 1·31 0·77
  5 1·22 0·66
  6 1·15 0·65
  7 1·02 0·69
  8 0·98 0·67
  9 0·92 0·67
10 0·90 0·68
Ratio of cumulative mortality in screening vs control by
years of randomization showing excess deaths in screened
group up to 7th year in women < 50 years and for the first
year in women > 50 years.
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of screening trial data. It is not surprising that all screening
trials (13 in all) have shown early excess mortality (breast,
lung, colon and now prostate).
  There is enough evidence to support both the hormonal
influence as well as SDA hypothesis. It is tempting to draw
a simile between the effect of observer on the observed in
quantum physics and SDA model in breast cancer. The
SDA model suggests that event of diagnosis and treatment
of the primary tumour changes its behaviour.  The SDA
model, induces a radical shift in the understanding of breast
cancer biology and offers opportunities to try modifiers of
biological potential for metastasis (e.g., tamoxifen, proges-
terone, anti-protease, angiostatin) in neo-adjuvant setting
and continues to support beneficial effects of early detec-
tion and surgery in the natural history of disease.
  It would be worthwhile to plan a trial comparing standard
practice (unplanned surgery as patient enrolls) versus sur-
gery during the luteal phase in pre-menopausal women.
Another possibility, based on circulating progesterone
studies, would be to compare primary progesterone treat-
ment (4–10 days prior to surgery) with standard practice.
Such a primary progesterone trial is already underway
and is conducted by the Indian Breast Group. Over 200
patients have so far been accrued. The details of the trial
would be available from Clinical Research Secretariat, Tata
Memorial Centre, Parel, Mumbai, India (Email:
tmhcrs@vsnl.com).
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